#Obesity medicine
Chronic weight management as a clinical specialty.
Zepbound versus obesity pills
Zepbound still has strong direct trial evidence as oral obesity medicines add useful, but not automatically superior, options.
Tirzepatide for sleep apnea
Tirzepatide reduced sleep-apnea severity in adults with obesity, but the evidence does not make it a universal substitute for CPAP.
Semaglutide meta-analysis: what it adds
A 2026 pooled analysis of four semaglutide trials in non-diabetic obesity lands on almost exactly the number STEP 1 reported in 2021.
GLP-1 and mood drugs: reading the signal
A 2026 Australian study links GLP-1 starts to fewer antidepressant starts. The design behind it decides how much that finding is worth.
Does Retatrutide cause muscle loss?
Phase 2 DXA data shows fat mass declining far more than lean mass, with lean loss proportional to other obesity treatments.
Respiratory safety of weight-loss drugs
A July 2026 ATS meta-analysis of 123 studies finds no added respiratory harm from four major weight-loss drugs, but flags a gap in asthma-specific evidence.
Compounders hold on in the GLP-1 market
A June 2026 Gallup survey found nearly 1 in 5 GLP-1 users still take compounded versions, despite FDA crackdowns and pharma lawsuits.
Surgery vs semaglutide: Reddit concerns
NLP of 45,972 Reddit comments: surgery patients cite pain; semaglutide users cite GI and psychological effects. Pre-op anxiety runs 4x higher than post-op.
Bariatric surgery volumes fell 39%
Epic Cosmos data show US bariatric surgery peaked in Q4 2022 and fell 39% by Q4 2025. Access to GLP-1 agonists before surgery splits sharply by insurance.
GLP-1 RAs in aging people with HIV
A 2026 review finds semaglutide reduces weight, improves cardiometabolic markers, and may slow epigenetic aging in people with HIV, but key safety gaps remain.
T2D and obesity: why treatment falls short
A July 2026 expert review finds clinicians undertreat obesity in type 2 diabetes, leaving a key driver of glycaemic failure and cardiovascular risk unaddressed.
Tirzepatide and kidney function in obesity
A 36-person real-world study found three months of tirzepatide improved eGFR in adults with obesity, with BMI change explaining about 19% of the kidney benefit.